Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

Figures & data

Table 1 Demographic Data and Endoscopic Appearance of Two Patient Groups

Characteristics	EACM (n = 99)	LACM (n = 98)	P-value
Age (year) (mean ± SD)	54.6±13.6	55.0±10.8	0.808
Gender (male/female)	56/43(56.6/43.4)	44/54(44.9/55.1)	0.101
Smoking	15(15.2)	7(7.1)	0.074
Alcohol drinking	24(24.2)	16(16.3)	0.167
Previous history of peptic ulcer	4(4.0)	3(3.1)	0.710
Endoscopic Findings
Gastritis	48(48.5)	49(50.0)	0.515
Gastric ulcer	29(29.3)	24(21.4)
Duodenal ulcer	15(15.2)	24(21.4)
Gastric and duodenal ulcer	7(7.1)	7(7.1)

Abbreviations: EACM, 7-day esomeprazole-based non-bismuth concomitant quadruple therapy; LACM, 7-day lansoprazole-based non-bismuth concomitant quadruple therapy; SD, standard deviation.

Table 2 The Major Outcomes of Two Period’s Groups

	Eradication Rates		P-value
	EACM (n = 99)	LACM (n = 98)
Intention-to-treat*(case number)	86.7% (91/105)	90.1% (91/101)	0.443
Per-protocol (case number)	91.9% (91/99)	92.9% (91/98)	0.804
Adverse events(case number)	11.1% (11/99)	10.2% (10/98)	0.837
Compliance (case number)	100.0% (99/99)	100.0% (98/98)	-

Note: *In this analysis, patients with unknown outcome are counted as treatment failures.

Abbreviations: EACM, 7-day esomeprazole-based non-bismuth concomitant quadruple therapy; LACM, 7-day lansoprazole-based non-bismuth concomitant quadruple therapy.

Table 3 Adverse Events of Two Groups

Adverse Event	EACM (n = 99)	LACM (n = 98)	P-value
Abdominal pain	4(4.0)	3(3.1)	0.710
Constipation	0	0	-
Diarrhea	1(1.0)	7(7.1)	0.029
Dizziness	1(1.0)	1(1.0)	0.994
Headache	3(3.0)	1(1.0)	0.317
Nausea/vomiting	3(3.0)	2(2.0)	0.659
Skin rash	0	0	-

Abbreviations: EACM, 7-day esomeprazole-based non-bismuth concomitant quadruple therapy; LACM, 7-day lansoprazole-based non-bismuth concomitant quadruple therapy.

Table 4 Univariate Analysis of the Clinical Factors Influencing the Efficacy of H. pylori Eradication Therapy

Principle Parameter		Case No.	Eradication Rate (%)	P-value
Age	<60 years	109/117	93.9	0.619
	≥60 years	73/80	91.3
Sex	Female	88/97	90.7	0.386
	Male	94/100	94.0
Previous history of peptic ulcer	(–)	172/187	92.0	0.439
	(+)	6/7	85.7
Helicobacter pylori eradication (per-protocol)	EACM	91/99	91.9	0.804
	LACM	91/98	92.9
Compliance	Good	197/197	100.0	–
	Poor	0	–
Culture (n=62)
Amoxicillin	Sensitive	56/62	90.3	–
	Resistant	0	–
Clarithromycin	Sensitive	48/53	90.6	0.875
	Resistant	8/9	88.9
Metronidazole	Sensitive	41/43	95.3	0.044
	Resistant	15/19	78.9
Dual resistance of clarithromycin and metronidazole	(–)	54/59	91.5	0.155
	(+)	2/3	66.7

Abbreviations: EACM, 7-day eEsomeprazole-based non-bismuth concomitant quadruple therapy; LACM, 7-day lansoprazole-based non-bismuth concomitant quadruple therapy.

Figure 1 Patients’ deposition.

Abbreviations: EACM, 7-day esomeprazole-based non-bismuth concomitant quadruple therapy; LACM, 7-day lansoprazole-based non-bismuth concomitant quadruple therapy; ITT, Intention-to-treat; PP, per-protocol.

Figure 2 Antibiotic resistances in the patients.

Abbreviations: AMX, amoxicillin; CLA, clarithromycin; MET, metronidazole; LFX, levofloxacin; TC, tetracycline; MET-CLA, dual metronidazole and clarithromycin resistance.